Charterhouse Capital Partners-backed SERB to acquire BTG Specialty Pharmaceuticals

December 01, 2020

Charterhouse Capital Partners LLP (“Charterhouse”), one of the longest established private equity firms operating in Europe, announces that its portfolio company Laboratoires SERB (“SERB”), a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, has entered into a definitive agreement to acquire BTG Specialty Pharmaceuticals from Boston Scientific.

BTG Specialty Pharmaceuticals provides antidotes and rescue medicines typically used in emergency rooms and intensive care units to treat patients with critical conditions, and therefore represents an excellent strategic fit for SERB. Its portfolio is manufactured from state-of-the-art facilities and is sold worldwide via a dedicated commercial team, and includes gold-standard brands in the emergency care space such as CroFab, DigiFab, and Voraxaze, which complement SERB’s existing specialty products  in critical care and rare diseases.

Since SERB was backed by Charterhouse in November 2017 it has experienced strong organic and inorganic growth, expanding its direct presence from three to nine countries, integrating seven strategic acquisitions, and doubling its revenues in the process. This latest acquisition will transform the group into a fully integrated specialty pharmaceutical platform that is well-positioned for further growth, with around 400 employees based in 11 offices, new manufacturing capabilities, and a direct commercial presence across all major pharmaceutical markets worldwide.